NASHVILLE, Tenn., December 11, 2025 — Vesalio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for enVast™, the first stent-based coronary thrombectomy technology designed to remove large clot burdens during primary percutaneous coronary intervention (PCI). This landmark clearance positions enVast™ as the first device to deliver stent-based mechanical engagement specifically engineered for removing thrombus in acute coronary syndromes, addressing a major unmet need in complex PCI procedures.
Science Significance
The enVast™ system introduces a novel stent-based clot retrieval mechanism, representing a significant evolution in the science of coronary thrombectomy. Conventional aspiration and mechanical systems often struggle to effectively capture and extract large or adherent thrombi, particularly in high-burden lesions that complicate revascularization. Vesalio’s proprietary Drop Zone Technology enables circumferential clot engagement, allowing the device to ensnare and remove thrombus with greater efficiency and more controlled retrieval. This enhances operator ability to restore coronary flow and may reduce downstream embolization, myocardial injury, and peri-procedural complications. The design reflects a paradigm shift toward precision-engineered, vessel-conforming thrombectomy tools, bridging lessons learned from the neurovascular stroke field into interventional cardiology.
Regulatory Significance
FDA’s 510(k) clearance validates enVast™ as a substantial technological advancement within an established cardiovascular device category, confirming that the device meets all safety, effectiveness, and performance standards. The clearance marks the first regulatory approval globally for a stent-based coronary thrombectomy system, signaling regulatory recognition of the need for improved tools to address large thrombus burdens. The device’s approval under the 510(k) pathway ensures that hospitals and interventional cardiologists may now adopt this technology within compliance frameworks governed by robust Quality System Regulation (QSR) and Good Manufacturing Practice (GMP) standards. This clearance establishes a regulatory foundation for future global approvals and sets a precedent for next-generation thrombectomy systems.
Business Significance
Advertisement
For Vesalio, the clearance of enVast™ represents a major commercial expansion milestone, opening U.S. market entry into the multibillion-dollar coronary intervention segment. The company already holds a strong presence in neurovascular thrombectomy, and this approval extends its technology platform into one of the most procedural-intensive cardiovascular domains. With more than 1 million PCI procedures performed annually in the United States, enVast™ provides Vesalio a strategic advantage as the first company to introduce a dedicated stent-based coronary thrombectomy device. The clearance also accelerates opportunities for partnerships, hospital system adoption, clinical training programs, and potential integration into PCI workflow guidelines. It reinforces Vesalio’s long-term strategy to diversify its thrombectomy portfolio across coronary, peripheral, and neurovascular markets.
Patients’ Significance
For patients suffering from acute myocardial infarction (AMI), timely and effective clot removal during PCI is vital to preserving heart muscle and reducing mortality. Large thrombus burdens increase the risk of no-reflow, microvascular obstruction, longer hospital stays, and adverse cardiac events. The enVast™ system offers a mechanical solution capable of directly capturing and extracting problematic thrombi, which could lead to improved reperfusion quality, fewer complications, and better overall outcomes. Its stent-based design may benefit patients who currently face limited options when aspiration or standard thrombectomy fails. As hospitals adopt this technology, patients with high-risk coronary blockages may experience safer, more reliable revascularization with long-term implications for survival and cardiac function.
Policy Significance
The introduction of enVast™ aligns with ongoing policy shifts encouraging innovation in cardiovascular intervention, especially for technologies that improve procedural safety and outcomes. As cardiovascular disease remains a leading cause of global mortality, regulatory bodies continue to prioritize tools that support guideline-based care, emergency response effectiveness, and resource optimization. FDA’s clearance underscores the agency’s commitment to facilitating access to next-generation interventional devices while upholding rigorous performance and manufacturing standards. The availability of novel thrombectomy solutions may also influence future updates to clinical practice guidelines and reimbursement frameworks, particularly as data accumulate on enVast’s impact in high-risk PCI populations.
Vesalio’s FDA 510(k) clearance of enVast™ marks a groundbreaking moment in coronary intervention, introducing the first stent-based technology specifically engineered for thrombectomy in PCI. With the potential to reshape procedural strategy, enhance clot retrieval, and improve patient outcomes, enVast™ represents a major advancement in interventional cardiology. As adoption grows, the device is poised to influence clinical practice, expand treatment capabilities, and reinforce the critical role of technological innovation in addressing acute cardiac emergencies.
Source: Vesalio press release
